InnoCare Pharma Limited (OTCMKTS:INCPF – Get Free Report) was the recipient of a large increase in short interest in August. As of August 31st, there was short interest totaling 215,000 shares, an increase of 73.4% from the August 15th total of 124,000 shares. Based on an average trading volume of 0 shares, the short-interest ratio is presently ∞ days.
InnoCare Pharma Stock Performance
OTCMKTS:INCPF remained flat at $1.55 during mid-day trading on Wednesday. The business’s 50 day moving average is $1.55 and its 200-day moving average is $1.55. InnoCare Pharma has a 52 week low of $1.55 and a 52 week high of $2.31.
Wall Street Analyst Weigh In
Separately, Morgan Stanley raised shares of InnoCare Pharma to an “overweight” rating in a research note on Thursday, May 28th. One investment analyst has rated the stock with a Buy rating, According to MarketBeat.com, InnoCare Pharma has a consensus rating of “Buy”.
About InnoCare Pharma
InnoCare Pharma Ltd is a China-based, clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small-molecule targeted therapies for oncology. Headquartered in Shenzhen, Guangdong Province, the company leverages structure-based drug design and comprehensive preclinical screening to advance drug candidates that address high-unmet-need cancers.
The company’s development pipeline comprises multiple small-molecule inhibitors in various stages of preclinical and early clinical evaluation.
Featured Stories
- Five stocks we like better than InnoCare Pharma
- AI Panic Hit Tech Stocks—But NVIDIA’s Growth Engine Is Intact
- 5 Buy-and-Hold Stocks Built to Weather a Volatile Market
- Movado’s Turnaround Gains Momentum
- Qualcomm’s Discount Could Vanish If Its AI Bet Pays Off
Receive News & Ratings for InnoCare Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InnoCare Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
